Effect of Bifidobacterium bifidum BF-1 on gastric protection and mucin production in an acute gastric injury rat model

Gomi, A.; Harima-Mizusawa, Naomi; Shibahara-Sone, Harue; Kano, Mitsuyoshi; Miyazaki, Katsumi; Ishikawa, Fumihiko

doi:10.3168/jds.2012-5950

Cited by 48 publications

(38 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has also been demonstrated that B. bifidum YIT 10347 has potential to inhibit H. pylori activity and the induction of IL-8 in H. pylori-infected gastric epithelial cells via the regulation of nuclear factor κB (NF-κB) signaling pathways (Shirasawa et al, 2010), to alleviate drug-induced acute injury due to the stimulated production of gastroprotective mucin in rat stomach (Gomi et al, 2013), and to adhere highly to both human gastric epithelial cells (GCIY cells) and mucin Figure 3. The ingestion of fermented milk containing Bifidobacterium bifidum YIT 10347 reduced the prevalence of lower abdominal symptoms in adults.…”

Section: Discussionmentioning

confidence: 99%

Health benefits of fermented milk containing Bifidobacterium bifidum YIT 10347 on gastric symptoms in adults

Gomi

Iino

Nonaka

et al. 2015

Journal of Dairy Science

Self Cite

View full text Add to dashboard Cite

We conducted a preliminary open trial (trial 1) and a double-blind, placebo-controlled, crossover trial (trial 2) to examine how fermented milk containing the probiotic Bifidobacterium bifidum YIT 10347 affects gastric and lower abdominal symptoms in adults taking no medication. In trial 1, subjects with or without gastric and lower abdominal symptoms ingested fermented milk containing B. bifidum YIT 10347 daily for 2 wk. In trial 2, subjects with gastric symptoms ingested fermented milk containing B. bifidum YIT 10347 (active preparation) or placebo daily for 2 wk, followed by crossover for 3 wk after a washout period. Before (baseline) and 1 and 2 wk after ingestion, subjects completed a questionnaire. In trial 1 (305 subjects), the prevalence of gastric and lower abdominal symptoms was 46 and 58%, respectively, at baseline. Ingestion of B. bifidum YIT 10347 significantly decreased the prevalence of gastric and lower abdominal symptoms from 45 to 33% at 1 wk and to 28% at 2 wk, and from 57 to 40% at 2 wk, respectively. In subjects with gastric symptoms at baseline, the average gastric symptom score per subject significantly decreased by 0.9 at 1 wk and 1.2 at 2 wk. In trial 2 (27 subjects), ingestion of the active preparation significantly decreased the average gastric symptoms score per subject by 1.0 at 1 wk and 1.1 at 2 wk, but ingestion of placebo milk had no effect. No side effects were reported by any subjects in either trial. We conclude that fermented milk containing B. bifidum YIT 10347 has the potential to provide health benefits by alleviating gastric symptoms in subjects taking no medication.

show abstract

Section: Discussionmentioning

confidence: 99%

Health benefits of fermented milk containing Bifidobacterium bifidum YIT 10347 on gastric symptoms in adults

Gomi

Iino

Nonaka

et al. 2015

Journal of Dairy Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…Living B. bifidum BF-1 and S. thermophilus YIT 2021 or vehicle was orally administered to rats, and acid-ethanol gastric injury was induced 2 h later. Mucin 5ac (muc5ac) gene expression in gastric corpus samples and gastric mucin production in stomach samples from the B. bifidum BF-1 group, but not the S. thermophilus YIT 2021 group, were significantly higher than those in the respective samples from the vehicle group [86] . Mirpuri et al [87] (2012) evaluated the enteral administration of LGG in mice with intestinal injury due to the administration of platelet-activating factor (PAF) and LPS.…”

Section: Other Inflammatory Disordersmentioning

confidence: 98%

Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics

Plaza‐Díaz¹

2014

WJG

180

120

View full text Add to dashboard Cite

The potential for the positive manipulation of the gut microbiome through the introduction of beneficial microbes, as also known as probiotics, is currently an active area of investigation. The FAO/WHO define probiotics as live microorganisms that confer a health benefit to the host when administered in adequate amounts. However, dead bacteria and bacterial molecular components may also exhibit probiotic properties. The results of clinical studies have demonstrated the clinical potential of probiotics in many pathologies, such as allergic diseases, diarrhea, inflammatory bowel disease and viral infection. Several mechanisms have been proposed to explain the beneficial effects of probiotics, most of which involve gene expression regulation in specific tissues, particularly the intestine and liver. Therefore, the modulation of gene expression mediated by probiotics is an important issue that warrants further investigation. In the present paper, we performed a systematic review of the probiotic-mediated modulation of gene expression that is associated with the immune system and inflammation. Between January 1990 to February 2014, PubMed was searched for articles that were published in English using the MeSH terms "probiotics" and "gene expression" combined with "intestines", "liver", "enterocytes", "antigen-presenting cells", "dendritic cells", "immune system", and "inflammation". Two hundred and five original articles matching these criteria were initially selected, although only those articles that included specific gene expression results (77) were later considered for this review and separated into three major topics: the regulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver. Particular strains of Bifidobacteria, Lactobacilli, Escherichia coli, Propionibacterium, Bacillus and Saccharomyces influence the gene expression of mucins, Toll-like receptors, caspases, nuclear factor-κB, and interleukins and lead mainly to an anti-inflammatory response in cultured enterocytes. In addition, the interaction of commensal bacteria and probiotics with the surface of antigen-presenting cells in vitro results in the downregulation of pro-inflammatory genes that are linked to inflammatory signaling pathways, whereas other anti-inflammatory genes are upregulated. The effects of probiotics have been extensively investigated in animal models ranging from fish to mice, rats and piglets. These bacteria induce a tolerogenic and hyporesponsive immune response in which many genes that are related to the immune system, in particular those genes expressing anti-inflammatory cytokines, are upregulated. By contrast, information related to gene expression in human intestinal cells mediated by the action of probiotics is scarce. There is a need for further clinical studies that evaluate the mechanism of action of probiotics both in healthy humans and in patients with chronic diseases. These types of clinical studies are necessary for addressing the influence of these microorga...

show abstract

“…Extensive research has been performed on the efficacy of various Lactobacillus strains on gastric ulcers (Dharmani et al, 2013;Khoder et al, 2016) either as single therapeutic agents or in combination with antibiotics (Boltin, 2016;Goderska et al, 2018). The majority of the investigated strains have been shown to inhibit or protect the gastric mucosal barrier through the up-regulation of prostaglandin E2 (Uchida and Kurakazu, 2004;Gotteland et al, 2006;Lam et al, 2007;Uchida et al, 2010), enhancement of mucus secretion (Gomi et al, 2013) or the regulation of inflammatory responses (Konturek et al, 2009;Şenol et al, 2014). Moreover, not only do these probiotics have prophylactic effects, but some of them also exert therapeutic effects through the enhancement of epithelial growth (Singh and Kaur, 2012), promotion of angiogenesis (Dharmani et al, 2013) and up-regulation effect on anti-inflammatory cytokines expression (Virchenko et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Amelioration of Alcohol Induced Gastric Ulcers Through the Administration of Lactobacillus plantarum APSulloc 331261 Isolated From Green Tea

et al. 2020

View full text Add to dashboard Cite

Gastric inflammation is an indication of gastric ulcers and possible other underlying gastric malignancies. Epidemiological studies have revealed that several Asian countries, including South Korea, suffer from a high incidence of gastric diseases derived from high levels of stress, alcoholic consumption, pyloric infection and usage of non-steroidal anti-inflammatory drugs (NSAIDs). Clinical treatments of gastric ulcers are generally limited to proton pump inhibitors that neutralize the stomach acid, and the application of antibiotics for Helicobacter pylori eradication, both of which are known to have a negative effect on the gut microbiota. The potential of probiotics for alleviating gastrointestinal diseases such as intestinal bowel syndrome and intestinal bowel disease receives increasing scientific interest. Probiotics may support the amelioration of disease-related symptoms through modulation of the gut microbiota without causing dysbiosis. In this study the potential of Lactobacillus plantarum APSulloc 331261 (GTB1 TM ), isolated from green tea, was investigated for alleviating gastric inflammation in an alcohol induced gastric ulcer murine model (positive control). Treatment with the test strain significantly influenced the expression of pro-inflammatory and anti-inflammatory biomarkers, interleukin 6 (IL6) and interleukin 10 (IL10), of which the former was downand the latter up-regulated when the alcohol induced mice were treated with the test strain. This positive effect was also indicated by less severe gastric morphological changes and the histological score of the gastric tissues. A significant increase in the abundance of Akkermansia within the GTB1 TM treated group compared to the positive control group also correlated with a decrease in the ratio of acetate over propionate. The increased levels of propionate in the GTB1 TM group appear to result from the impact of the test strain on the microbial population and the resulting metabolic activities. Moreover, there was a significant increase in beta-diversity in the group that received GTB1 TM over that of the alcohol induced control group.

show abstract

Effect of Bifidobacterium bifidum BF-1 on gastric protection and mucin production in an acute gastric injury rat model

Cited by 48 publications

References 12 publications

Health benefits of fermented milk containing Bifidobacterium bifidum YIT 10347 on gastric symptoms in adults

Health benefits of fermented milk containing Bifidobacterium bifidum YIT 10347 on gastric symptoms in adults

Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics

Amelioration of Alcohol Induced Gastric Ulcers Through the Administration of Lactobacillus plantarum APSulloc 331261 Isolated From Green Tea

Contact Info

Product

Resources

About